Skip to main content
. Author manuscript; available in PMC: 2024 Feb 5.
Published in final edited form as: Ann Allergy Asthma Immunol. 2023 Aug 27;131(6):745–751.e11. doi: 10.1016/j.anai.2023.08.595

Figure 2.

Figure 2.

Most burdensome ICS adverse effects (with or without LABA) organized by mean rating of responses.

ICS, inhaled corticosteroids; LABA, long-acting beta agonist.